| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -- To address the emergence of the synthetic biology industry and to promote its potential, a group of individuals and companies announced the formation of the Synthetic Biology Industry Association (SynBIA) in Cambridge, Massachusetts last week. The goal of the association is to provide a forum for individuals and commercial interests to discuss the new industry, address its opportunities and its challenges, and advocate for its development. Founding members include representatives of febit, GENEART, Ginkgo BioWorks, Biosearch Technologies and Sutro Biopharma.
The association will serve as the trade association home for a diverse group of companies and individuals involved in synthetic biology development, including companies involved in gene synthesis, pharmaceutical development, energy development, and pollution control. The goal is to responsibly join the public discussion and promote development.
Among the more specific goals of SynBIA is an informed discussion about the risks and rewards of development. This includes participation in the discussion of dual use and in the current discussion regarding voluntary screening obligations (codes of conduct). Association members are active participants in meetings with the FBI, the National Academy of Sciences and the Association for the Advancement of Science relating to the developing synthetic biology field.
Founding Chairman JD Kittle noted, "The industry has strong potential to be a part of the solution to problems in the world's health, energy and environmental arenas. SynBIA plans to be a part of the discussion advocating for increased funding to enhance participation in these areas."
Founding Board member, Mark Waxman of Foley & Lardner, also pointed out that with the increasing visibility, IP portfolios, and transaction volume, there is a developing need for an association to address industry issues
'/>"/>
| SOURCE Synthetic Biology Industry Association (SynBIA) Copyright©2009 PR Newswire. All rights reserved |